<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>SigmaDock: Untwisting Molecular Docking With Fragment-Based SE(3) Diffusion - Health AI Hub</title>
    <meta name="description" content="SigmaDock introduces a novel SE(3) Riemannian diffusion model for molecular docking that decomposes ligands into rigid-body fragments and learns to reassemble t">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>SigmaDock: Untwisting Molecular Docking With Fragment-Based SE(3) Diffusion</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.04854v1" target="_blank">2511.04854v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-06
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Alvaro Prat, Leo Zhang, Charlotte M. Deane, Yee Whye Teh, Garrett M. Morris
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, q-bio.QM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.04854v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.04854v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">SigmaDock introduces a novel SE(3) Riemannian diffusion model for molecular docking that decomposes ligands into rigid-body fragments and learns to reassemble them within a protein binding pocket. This fragment-based approach achieves state-of-the-art performance, with over 79.9% Top-1 success rates on the PoseBusters set, significantly outperforming other deep learning methods. Crucially, SigmaDock is the first deep learning model to surpass classical physics-based docking methods, marking a significant leap in the reliability and feasibility of AI for molecular modeling.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Accurate and efficient molecular docking is a cornerstone of rational drug design, enabling the precise identification of potential drug candidates and understanding their binding mechanisms to biological targets. Improved docking accuracy directly accelerates the drug discovery and development process.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>SigmaDock is an AI model (specifically, a deep learning SE(3) Riemannian diffusion model) designed to predict the binding pose of a ligand to a protein. In a health context, this AI application directly accelerates and improves the early stages of drug discovery by providing more accurate and faster methods for identifying potential drug candidates and understanding their interactions with biological targets, ultimately leading to the development of new medicines and therapies.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Molecular docking, essential for drug discovery, faces challenges with existing generative methods regarding chemical plausibility, generalizability, and computational cost.</li>
                    
                    <li>SigmaDock employs a novel fragmentation scheme, leveraging structural chemistry biases, to decompose ligands into rigid-body fragments.</li>
                    
                    <li>The model utilizes an SE(3) Riemannian diffusion process to generate poses by learning to reassemble these fragments accurately within the protein's binding pocket.</li>
                    
                    <li>Operating at the fragment level in SE(3) exploits well-established geometric priors, simplifying diffusion processes and stabilizing training dynamics.</li>
                    
                    <li>SigmaDock achieved state-of-the-art performance with Top-1 success rates (RMSD<2 & PB-valid) above 79.9% on the PoseBusters set, significantly higher than 12.7-30.8% reported by other deep learning approaches.</li>
                    
                    <li>It is the first deep learning method to surpass classical physics-based docking under the PoseBusters train-test split, demonstrating superior reliability.</li>
                    
                    <li>The model shows consistent generalisation to unseen proteins, addressing a key limitation of prior deep learning generative models.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>SigmaDock utilizes a novel fragmentation scheme to decompose ligands into rigid-body fragments, incorporating inductive biases from structural chemistry. Building on this decomposition, it employs an SE(3) Riemannian diffusion model that learns to reassemble these fragments precisely within the protein binding pocket, thereby generating accurate ligand binding poses. This fragment-based approach in SE(3) space leverages geometric priors to enhance stability and efficiency.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>SigmaDock achieved state-of-the-art Top-1 success rates exceeding 79.9% (RMSD<2 and PB-valid) on the PoseBusters dataset, which represents a significant improvement over previous deep learning methods (12.7-30.8%). Crucially, it is the first deep learning approach to demonstrably outperform classical physics-based docking under the same train-test split, showcasing enhanced reliability and consistent generalization to unseen proteins.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This breakthrough in molecular docking significantly enhances the accuracy and speed of identifying potential drug candidates. By providing more reliable predictions of how molecules bind to therapeutic targets, SigmaDock can accelerate the preclinical phases of drug discovery, reduce development costs, and facilitate the design of more effective and safer medicines, ultimately benefiting patients with novel therapies sooner.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly detailed for SigmaDock within the abstract. The paper focuses on SigmaDock's ability to address and overcome limitations common to previous generative deep learning approaches in molecular docking (e.g., chemically implausible outputs, poor generalisability, high computational cost).</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the abstract. However, the demonstrated success of SigmaDock opens avenues for further applications in drug design, such as integrating it into comprehensive virtual screening workflows, optimizing lead compounds, or potentially extending its principles to other complex molecular interactions beyond protein-ligand binding to further accelerate therapeutic innovation.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                    <span class="tag">Pharmaceutical Research</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">molecular docking</span>
                    
                    <span class="tag tag-keyword">drug discovery</span>
                    
                    <span class="tag tag-keyword">SE(3) diffusion</span>
                    
                    <span class="tag tag-keyword">deep learning</span>
                    
                    <span class="tag tag-keyword">fragment-based</span>
                    
                    <span class="tag tag-keyword">pose prediction</span>
                    
                    <span class="tag tag-keyword">generative models</span>
                    
                    <span class="tag tag-keyword">protein-ligand binding</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Determining the binding pose of a ligand to a protein, known as molecular
docking, is a fundamental task in drug discovery. Generative approaches promise
faster, improved, and more diverse pose sampling than physics-based methods,
but are often hindered by chemically implausible outputs, poor
generalisability, and high computational cost. To address these challenges, we
introduce a novel fragmentation scheme, leveraging inductive biases from
structural chemistry, to decompose ligands into rigid-body fragments. Building
on this decomposition, we present SigmaDock, an SE(3) Riemannian diffusion
model that generates poses by learning to reassemble these rigid bodies within
the binding pocket. By operating at the level of fragments in SE(3), SigmaDock
exploits well-established geometric priors while avoiding overly complex
diffusion processes and unstable training dynamics. Experimentally, we show
SigmaDock achieves state-of-the-art performance, reaching Top-1 success rates
(RMSD<2 & PB-valid) above 79.9% on the PoseBusters set, compared to 12.7-30.8%
reported by recent deep learning approaches, whilst demonstrating consistent
generalisation to unseen proteins. SigmaDock is the first deep learning
approach to surpass classical physics-based docking under the PB train-test
split, marking a significant leap forward in the reliability and feasibility of
deep learning for molecular modelling.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>Preprint</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>